Goldberg O, et al. - Researchers evaluated colchicine treatment for its safety and efficacy in children with familial Mediterranean fever (FMF) <4 years old. From the departmental database, they included a cohort of 89 children with FMF: 41 first treated before age 4 years, and 48 first treated at age 4-8 years. Findings revealed equal efficacy and safety of colchicine for use in patients with FMF under 4 years old, with no difference in response from older pediatric patients. Diarrhea was identified to be the most frequent adverse event, with a prevalence of 24.4% in the younger group and 22. 9% in the older group respectively.